<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01700218</url>
  </required_header>
  <id_info>
    <org_study_id>24-537 ex 11/12</org_study_id>
    <nct_id>NCT01700218</nct_id>
  </id_info>
  <brief_title>Integrated Telemonitoring and Nurse Support Evaluation</brief_title>
  <acronym>INTENSE-HF</acronym>
  <official_title>Integrated Telemonitoring and Nurse Support Evaluation in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig Boltzmann Institute for translational heart failure research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIT Austrian Institute of Technology GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test a new medical device for optimizing treatment of heart
      failure and compare its effect on outcome of patients with a recent hospitalization for
      worsening heart failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients after an episode of acute heart failure have an increased risk of rehospitalisation
      and impaired prognosis for survival. Neither a sole mobile nurse support nor a sole
      telemonitoring system has been able to provide consistent data on a beneficial influence on
      prognosis. Furthermore, the influence of frequent measurements of NT-pro-BNP in a home
      setting of heart failure patients has not been investigated so far.

      This study will test a new medical device (software) for optimizing treatment of heart
      failure patients and evaluate its impact on outcome of these patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality and hospitalization for worsening heart failure</measure>
    <time_frame>12 months</time_frame>
    <description>outcome assessment will be done by a blinded committee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>days alive and out of hospital</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>exploratory endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>The exploratory endpoint will focus on the percentage of optimal dosing (according to current ESC-guidelines) for ACE-inhibitors, angiotensin receptor blockers and beta-blockers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>telemonitoring</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients in the control arm will not record any vital parameter</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>telemonitoring</intervention_name>
    <arm_group_label>telemonitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute systolic heart failure with admission for at least 4 consecutive days

          -  treatment with an ACE-inhibitor/angiotensin receptor blocker, beta-blocker,
             mineralocorticoid receptor antagonist according to current ESC-guidelines

          -  treatment with a loop diuretic

          -  stable renal function (eGFR according to MDRD of at least 30ml)

          -  written informed consent

          -  minimum age of 18 years

        Exclusion Criteria:

          -  unstable coronary artery disease with revascularisation of any type within the last
             two months

          -  planned revascularisation or operation for valvular heart disease within the next 6
             months

          -  planned heart transplantation

          -  uncontrolled hypertension

          -  active myocarditis

          -  malignant disease with a life expectancy of less than 18 months

          -  chronic use of high-dose NSAID or COX-2-inhibitors

          -  psychiatric disorders that make it unlikely to understand the protocol

          -  participation in an other randomized trial

          -  inability to operate a smartphone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedrich M Fruhwald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Friedrich M Fruhwald, MD</last_name>
    <phone>+43-316-385</phone>
    <phone_ext>12544</phone_ext>
    <email>friedrich.fruhwald@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Scherr, MD</last_name>
    <phone>+43-316-385</phone>
    <phone_ext>12544</phone_ext>
    <email>daniel.scherr@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich M Fruhwald, MD</last_name>
      <phone>+43-316-385</phone>
      <phone_ext>12544</phone_ext>
      <email>friedrich.fruhwald@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Scherr, MD</last_name>
      <phone>+43-316-385</phone>
      <phone_ext>12544</phone_ext>
      <email>daniel.scherr@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Friedrich M Fruhwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Scherr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://heart.lbg.ac.at</url>
    <description>website of the Ludwig Boltzmann Institute for translational heart failure research</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2012</study_first_posted>
  <last_update_submitted>November 23, 2014</last_update_submitted>
  <last_update_submitted_qc>November 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>telemonitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

